請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71309
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭永銘 | |
dc.contributor.author | Jau-Yu Liau | en |
dc.contributor.author | 廖肇裕 | zh_TW |
dc.date.accessioned | 2021-06-17T05:04:11Z | - |
dc.date.available | 2018-08-01 | |
dc.date.copyright | 2018-08-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-07-24 | |
dc.identifier.citation | 1. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006; 48: 13-21.
2. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013; 152: 390-393. 3. Harle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci U S A 1996; 93: 6476-6481. 4. Norrback KF, Roos G. Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 1997; 33: 774-780. 5. Royle NJ, Foxon J, Jeyapalan JN et al. Telomere length maintenance--an ALTernative mechanism. Cytogenet Genome Res 2008; 122: 281-291. 6. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11: 319-330. 7. Henson JD, Reddel RR. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett 2010; 584: 3800-3811. 8. Heaphy CM, Subhawong AP, Hong SM et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011; 179: 1608-1615. 9. Henson JD, Hannay JA, McCarthy SW et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005; 11: 217-225. 10. Montgomery E, Argani P, Hicks JL et al. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004; 164: 1523-1529. 11. McDonald KL, McDonnell J, Muntoni A et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 2010; 69: 729-736. 12. Hakin-Smith V, Jellinek DA, Levy D et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003; 361: 836-838. 13. Nguyen DN, Heaphy CM, de Wilde RF et al. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 2013; 23: 237-243. 14. Ulaner GA, Huang HY, Otero J et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003; 63: 1759-1763. 15. Venturini L, Motta R, Gronchi A et al. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer 2010; 10: 254. 16. Costa A, Daidone MG, Daprai L et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006; 66: 8918-8924. 17. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203. 18. Heaphy CM, de Wilde RF, Jiao Y et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333: 425. 19. Abedalthagafi M, Phillips JJ, Kim GE et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol 2013; 26: 1425-1432. 20. Lovejoy CA, Li W, Reisenweber S et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012; 8: e1002772. 21. Picketts DJ, Higgs DR, Bachoo S et al. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet 1996; 5: 1899-1907. 22. Tang J, Wu S, Liu H et al. A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. J Biol Chem 2004; 279: 20369-20377. 23. Law MJ, Lower KM, Voon HP et al. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell 2010; 143: 367-378. 24. Lewis PW, Elsaesser SJ, Noh KM et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A 2010; 107: 14075-14080. 25. Drane P, Ouararhni K, Depaux A et al. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010; 24: 1253-1265. 26. Goldberg AD, Banaszynski LA, Noh KM et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010; 140: 678-691. 27. Wong LH, McGhie JD, Sim M et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res 2010; 20: 351-360. 28. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell 1995; 80: 837-845. 29. Coindre JM, Terrier P, Bui NB et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996; 14: 869-877. 30. Gladdy RA, Qin LX, Moraco N et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol 2010; 28: 2064-2069. 31. Killela PJ, Reitman ZJ, Jiao Y et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013; 110: 6021-6026. 32. Griewank KG, Schilling B, Murali R et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol 2014; 27: 502-508. 33. Slatter TL, Tan X, Yuen YC et al. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells. J Pathol 2012; 226: 509-518. 34. Chen X, Bahrami A, Pappo A et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014; 7: 104-112. 35. Fishbein L, Khare S, Wubbenhorst B et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 2015; 6: 6140. 36. Pinto EM, Chen X, Easton J et al. Genomic landscape of paediatric adrenocortical tumours. Nat Commun 2015; 6: 6302. 37. Chen SF, Kasajima A, Yazdani S et al. Clinicopathologic significance of immunostaining of alpha-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors. Hum Pathol 2013; 44: 2199-2203. 38. Jiao Y, Killela PJ, Reitman ZJ et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3: 709-722. 39. Ulaner GA, Hoffman AR, Otero J et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004; 41: 155-162. 40. Koelsche C, Renner M, Johann P et al. Differential nuclear ATRX expression in sarcomas. Histopathology 2016; 68: 738-745. 41. Lee JC, Jeng YM, Liau JY et al. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. Mod Pathol 2015; 28: 1064-1073. 42. Koelsche C, Renner M, Hartmann W et al. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res 2014; 33: 33. 43. Liau JY, Tsai JH, Jeng YM et al. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Am J Surg Pathol 2015; 39: 236-244. 44. Panse G, Chrisinger JS, Leung CH et al. Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. Histopathology 2018; 72: 239-247. 45. Guo T, Zhang L, Chang NE et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 2011; 50: 25-33. 46. Manner J, Radlwimmer B, Hohenberger P et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2010; 176: 34-39. 47. Mentzel T, Schildhaus HU, Palmedo G et al. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol 2012; 25: 75-85. 48. Wu KJ, Grandori C, Amacker M et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220-224. 49. Lebel R, McDuff FO, Lavigne P, Grandbois M. Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box sequences on the hTERT promoter. Biochemistry 2007; 46: 10279-10286. 50. O'Sullivan RJ, Arnoult N, Lackner DH et al. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. Nat Struct Mol Biol 2014; 21: 167-174. 51. Willems SM, Debiec-Rychter M, Szuhai K et al. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 2006; 19: 407-416. 52. Lefevre SH, Vogt N, Dutrillaux AM et al. Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene 2001; 20: 8092-8099. 53. Ram R, Uziel O, Eldan O et al. Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res 2009; 15: 914-923. 54. Gunawan B, von Heydebreck A, Sander B et al. An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J Pathol 2007; 211: 463-470. 55. El-Rifai W, Sarlomo-Rikala M, Andersson LC et al. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000; 60: 3899-3903. 56. Assamaki R, Sarlomo-Rikala M, Lopez-Guerrero JA et al. Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors. Genes Chromosomes Cancer 2007; 46: 564-576. 57. Kawai J, Kodera Y, Fujiwara M et al. Telomerase activity as prognostic factor in gastrointestinal stromal tumors of the stomach. Hepatogastroenterology 2005; 52: 959-964. 58. Antonescu CR, Romeo S, Zhang L et al. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. Am J Surg Pathol 2013; 37: 385-392. 59. Liegl B, Hornick JL, Antonescu CR et al. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol 2009; 33: 218-226. 60. Hechtman JF, Zehir A, Mitchell T et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes Cancer 2015; 54: 177-184. 61. Mantripragada KK, Caley M, Stephens P et al. Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Genes Chromosomes Cancer 2008; 47: 238-246. 62. Gunther T, Schneider-Stock R, Hackel C et al. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin Cancer Res 2000; 6: 1811-1818. 63. Ohali A, Avigad S, Naumov I et al. Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 2008; 47: 965-970. 64. Bridge JA, Liu J, Qualman SJ et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 2002; 33: 310-321. 65. Qualman S, Lynch J, Bridge J et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer 2008; 113: 3242-3247. 66. Errani C, Zhang L, Sung YS et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011; 50: 644-653. 67. Tanas MR, Sboner A, Oliveira AM et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011; 3: 98ra82. 68. Bahrami A, Lee S, Schaefer IM et al. TERT promoter mutations and prognosis in solitary fibrous tumor. Mod Pathol 2016; 29: 1511-1522. 69. Modena P, Lualdi E, Facchinetti F et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 2005; 65: 4012-4019. 70. Schwartzentruber J, Korshunov A, Liu XY et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482: 226-231. 71. Flynn RL, Cox KE, Jeitany M et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015; 347: 273-277. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71309 | - |
dc.description.abstract | 替代性端粒延長機制是一種無涉端粒酶而能使端粒長度維持,進而使癌細胞持續具有細胞分裂能力的一種機制。目前推測此機制是利用染色體的同源重組及修復機制,複製其他染色體上的端粒及其他DNA序列來維持另一條染色體的端粒長度。使用此機制來維持端粒的細胞特徵為端粒長度長短不一,並且某些染色體可能具有極長的端粒。這些現象可用南方墨點法或端粒的螢光原位雜合實驗觀察。軟組織肉瘤和膠狀細胞瘤為主要使用此機制的癌症,之前的胰臟神經內分泌腫瘤瘤研究發現此機制和ATRX或DAXX的失去活性有顯著相關。我們使用端粒的螢光原位雜合以及ATRX/DAXX的免疫組織化學染色來探討此機制在各種軟組織腫瘤的發生率,其和ATRX/DAXX之表現的相關性,以及可能的臨床病理特性。
我們總共分析了535例軟組織腫瘤,包含456例軟組織肉瘤(含23例胃腸道間質瘤及20例卡波西氏肉瘤)以及79例組織學上有不典型表現但不足以診斷為惡性之子宮平滑肌腫瘤。在456例軟組織肉瘤中,共有67例失去ATRX表現(15%),其中有二例同時部分失去DAXX表現(均為血管肉瘤)。就組織型態學上來看,未分化肉瘤(12/35, 34%)、平滑肌肉瘤(30/92, 33%)、骨肉瘤(4/18, 22%)及血管肉瘤(16/88, 18%)為失去ATRX表現比例最高的數種腫瘤。少部分之胚胎性橫紋肌肉瘤(1/9, 11%)、上皮樣血管內皮瘤(1/11, 9%)、惡性周邊神經鞘瘤(1/17, 6%)、及粘液纖維肉瘤(1/27, 4%)也可見失去ATRX表現。在23例胃腸道間質瘤中有一例部分失去ATRX表現(1/23, 4%)。在非惡性之平滑肌腫瘤中,有一例惡性潛能未定型平滑肌瘤(1/12, 8%)失去ATRX表現。其餘腫瘤之ATRX/DAXX表現為正常。 共有405例腫瘤得到可判讀之端粒螢光原位雜合,共計有334例軟組織肉瘤及71例非惡性之平滑肌腫瘤。我們的結果顯示共有123例為替代性端粒延長機制陽性,包含118例軟組織肉瘤(118/334, 35%)、4例惡性潛能未定型平滑肌瘤(4/12, 33%)以及1例非典型平滑肌瘤(1/25, 4%)。就軟組織肉瘤的形態學上來看,替代性端粒延長機制在未分化肉瘤(22/34, 65%)、平滑肌肉瘤(51/86, 59%)、粘液纖維肉瘤(19/25, 76%)中最常見,在一部分的血管肉瘤(17/70, 24%), 放射治療後肉瘤(3/15, 20%)、惡性周邊神經鞘瘤(3/14, 21%)、胚胎性橫紋肌肉瘤(1/8, 13%)、上皮樣血管內皮瘤(1/7, 14%)及胃腸道基質瘤(1/16, 6%)也可見到替代性端粒延長機制。除了2例平滑肌肉瘤外,其餘ATRX失去表現之腫瘤均為替代性端粒延長機制陽性(P < 0.001)。在321例細胞遺傳學複雜的軟組織肉瘤中,共有65例(20%)失去ATRX表現,且有116例(116/252, 46%)為替代性端粒延長機制陽性,二者之比例均遠較基因融合之肉瘤為高(失去ATRX表現及替代性端粒延長機制分別為1%及2%;二者之P值均小於0.001)。在平滑肌腫瘤及血管肉瘤中我們也探討了替代性端粒延長機制及失去ATRX的臨床病理意義。我們發現替代性端粒延長機制在平滑肌肉瘤中為一不良之預後因子,在血管肉瘤中則兩種特性均特別常見於肝臟之血管肉瘤。我們也嘗試探討端例螢光原位雜合對於組織學上有不典型表現但不足以診斷為惡性之子宮平滑肌腫瘤的診斷預後判斷價值。在4例替代性端粒延長機制陽性的惡性潛能未定型平滑肌瘤中,有3例後來復發或轉移,顯示此方法有輔助診斷及預後判斷的潛力。 總結為替代性端粒延長機制對於軟組織肉瘤,特別是對於細胞遺傳學複雜的肉瘤是一個重要的維持端粒長度的機制。此機制和失去ATRX高度相關,並且在平滑肌腫瘤中是一個不良的預後因子。最近已有文獻報告指出抑制ATR酵素可能可針對性地殺死替代性端粒延長機制陽性之細胞,因此此種療法或許有潛力在將來作為對抗這些預後不良的腫瘤的希望。 | zh_TW |
dc.description.abstract | Alternative lengthening of telomeres (ALT) is a telomerase-unrelated telomere maintenance mechanism that maintain the cell division ability in cancer cells. Currently it is supposed that homologous recombination and DNA repair are utilized in this mechanism, which copy the telomeres and other DNA sequences from other chromosomes to maintain the telomere length. ALT positive cells are characterized by telomere length heterogeneity and some chromosomes may have extremely long telomeres. These phenomena can be visualized by Southern blotting or telomere fluorescent in situ hybridization (FISH). Among the cancers, soft tissue sarcomas and gliomas are frequently ALT positive. In previous studies ALT has been shown to be highly correlated with loss of ATRX or DAXX in pancreatic neuroendocrine tumors. We used telomere FISH and ATRX/DAXX immunohistochemistry to determine the frequencies of this mechanism in different sarcoma types, its correlation with ATRX/DAXX expression, and potential clinicopathological features.
In total, we analyzed 535 soft tissue tumors, including 456 soft tissue sarcomas (including 23 gastrointestinal stromal tumors [GIST] and 20 Kaposi sarcoma) and 79 cases of uterine smooth muscle tumors that exhibit atypical histological features but fall short of the diagnosis of leiomyosarcoma. Loss of ATRX expression was seen in 67 tumors (15%) of the 456 soft tissue sarcomas, and partial loss of DAXX was observed in 2 ATRX-deficient tumors (both were angiosarcomas). By the histological subtype, undifferentiated sarcoma (12/35, 34%), leiomyosarcoma (30/92, 33%), osteosarcoma (4/18, 22%) and angiosarcoma (16/88, 18%) were the major tumor types most frequently exhibited loss of ATRX. Loss of ATRX expression was also seen in small proportions of embryonal rhabdomyosarcoma (1/9, 11%), epithelioid hemangioendothelioma (1/11, 9%), malignant peripheral nerve sheath tumor (MPNST, 1/17, 6%) and myxofibrosarcoma (1/27, 4%). One GIST exhibited focal loss of ATRX expression (1/23, 4%). In non-leiomyosarcomatous smooth muscle tumors, loss of ATRX expression was observed in 1 smooth muscle tumor of uncertain malignant potential (STUMP). Other tumors exhibited retained ATRX/DAXX expression. Interpretable telomere FISH was obtained in 405 tumors, including 334 soft tissue sarcomas and 71 non-leiomyosarcomatous smooth muscle tumors. The results showed that 123 tumors were positive for ALT, including 118 soft tissue sarcomas (118/334, 35%), 4 STUMPs (4/12, 33%) and 1 atypical leiomyoma (1/25, 4%). By the histological subtype, ALT was most commonly seen in undifferentiated sarcoma (22/34, 65%), leiomyosarcoma (51/86, 59%) and myxofibrosarcoma (19/25, 76%). ALT was also observed in subsets of angiosarcoma (17/70, 24%), post-irradiation sarcoma (3/15, 20%), MPNST (3/14, 21%), embryonal rhabdomyosarcoma (1/8, 13%), epithelioid hemangioendothelioma (1/7, 14%) and GIST (1/16, 6%). Except for 2 leiomyosarcomas, all ATRX-deficient tumors were ALT positive (P < 0.001). In 321 cytogenetically complex sarcomas, 65 cases were ATRX deficient (20%), and 116 cases were ALT positive (46%). Both features were much more commonly seen than in gene fusion-associated sarcomas (both P < 0.001). We also studied the clinicopathological significance of ALT and loss of ATRX in leiomyosarcomas and angiosarcomas. We found that ALT was an unfavorable prognostic factor in leiomyosarcomas, and in angiosarcomas these two features were particularly common in primary hepatic tumors. We also attempted to investigate the diagnostic and prognostic values of telomere FISH in non-leiomyosarcomatous uterine smooth muscle tumors. Among the 4 ALT positive STUMPs, 3 exhibited tumor recurrence and/or metastasis. Our results demonstrated that this method has potential utilities in the diagnosis and prognostication. In summary, our results showed that ALT is an important telomere maintenance mechanism in soft tissue sarcomas, particularly in cytogenetically complex sarcomas. This mechanism was highly associated with loss of ATRX and was an unfavorable prognostic factor in smooth muscle tumors. Recent studies have shown that inhibition of ATR can selectively kill the ALT positive cells. This therapy may be promising in the future to treat these tumors. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T05:04:11Z (GMT). No. of bitstreams: 1 ntu-107-D01444004-1.pdf: 4132596 bytes, checksum: e7dbd78038a0837f9a0750bde1db8884 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 論文口試委員審定書…………………………………………………... I
誌謝……………………………………………………………………... II 中文摘要………………………………………………………………... III 英文摘要………………………………………………………………... V Chapter 1 Introduction……………………………………………... 1 Chapter 2 Materials and Methods…………………………………. 5 2.1 Tumor samples…………………………………………………. 5 2.2 Immunohistochemistry…………………………………………. 6 2.3 Telomere fluorescent in situ hybridization……………………... 7 2.4 DNA flow cytometry…………………………………………… 9 2.5 Statistical analysis………………………………………………. 9 Chapter 3 Results…………………………………………………… 11 3.1 Loss of ATRX/DAXX expression in sarcomas……………….... 11 3.1.1 Loss of ATRX/DAXX expression in cytogenetically complex sarcomas……………………………………………………………………………... 11 3.1.2 Loss of ATRX/DAXX expression in gene fusion-associated sarcomas, gastrointestinal stromal tumors and epithelioid sarcomas………………... 12 3.2 ALT and its relationship with loss of ATRX/DAXX expression in sarcomas……………………………………………………………………………... 13 3.2.1 ALT and its relationship with loss of ATRX/DAXX expression in cytogenetically complex sarcomas……………………………………………………14 3.2.2 ALT and its relationship with loss of ATRX/DAXX expression in gene fusion-associated sarcomas, gastrointestinal stromal tumors and epithelioid sarcomas……………………………………………………………………………... 16 3.3 Clinicopathological features of ALT and loss of ATRX/DAXX expression in smooth muscle tumors………………………………………………… 18 3.3.1 Clinicopathological features of leiomyosarcomas……………. 18 3.3.2 Loss of ATRX Expression in leiomyosarcomas……………… 20 3.3.3 Frequent ALT in leiomyosarcomas…………………………… 21 3.3.4 ALT and its relationship with loss of ATRX/DAXX expression in uterine smooth muscle tumors with atypical/borderline histological features………. 22 3.3.5 Survival analysis of leiomyosarcoma patients………………... 23 3.3.6 DNA flow cytometry for leiomyosarcomas and its histopathological correlations………………………………………………………... 24 3.4 Clinicopathological features of ALT and loss of ATRX/DAXX expression in angiosarcomas, epithelioid hemangioendotheliomas and Kaposi sarcomas……………………………………………………………………………... 25 3.4.1 Clinicopathological features………………………………….. 25 3.4.2 Loss of ATRX and DAXX expression in angiosarcomas and epithelioid hemangioendotheliomas…………………………………………………. 26 3.4.3 ALT in angiosarcomas and epithelioid hemangioendotheliomas……………………………………………………………... 28 3.4.4. Survival analysis……………………………………………... 29 Chapter 4 Discussion………………………………………………... 30 4.1 Telomere-maintenance Mechanisms in Soft Tissue Sarcomas…. 30 4.2 ALT and Loss of ATRX/DAXX………………………………... 31 4.3 ALT and Loss of ATRX/DAXX Expression in Soft Tissue Sarcomas……………………………………………………………………………... 32 Chapter 5 Conclusion……………………………………………….. 45 References 圖目錄 Figure 1 Histology, ATRX/DAXX immunohistochemistry and telomere FISH in undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumor……………………………….. 57 Figure 2 Histology, ATRX/DAXX immunohistochemistry and telomere FISH in anaplastic embryonal rhabdomyosarcoma, gastrointestinal stromal tumor, myxofibrosarcoma and osteosarcoma…………………………… 58 Figure 3 Histology, ATRX/DAXX immunohistochemistry and telomere FISH in malignant solitary fibrous tumor, poorly differentiated synovial sarcoma and dermatofibrosarcoma protuberans………………………… 59 Figure 4 Histology, ATRX/DAXX immunohistochemistry and telomere FISH in ATRX-deficient and ATRX-proficient leiomyosarcomas……… 60 Figure 5 Degree of differentiation, FNCLCC grade and ALT status were associated with overall survival of leiomyosarcoma patients…………... 61 Figure 6 Histology, ATRX/DAXX immunohistochemistry and telomere FISH in uterine smooth muscle tumor of uncertain malignant potentials………………………………………………………………... 62 Figure 7 Histology, ATRX/DAXX immunohistochemistry and telomere FISH in atypical leiomyoma and benign metastasizing leiomyoma……. 63 Figure 8 Histology and DNA flow cytometry histogram of leiomyosarcomas………………………………………………………... 64 Figure 9 Bar chart of the proportion of ATRX-deficient and ALT-positive angiosarcomas in various organs………………………………. 65 Figure 10 Histology and ATRX immunohistochemistry in ATRX-deficient angiosarcomas………………………………………………… 66 Figure 11 Histology, ATRX immunohistochemistry and telomere FISH in the ATRX-deficient epithelioid hemangioendothelioma………………... 67 Figure 12 Histology, ATRX/DAXX immunohistochemistry and telomere FISH in ATRX-deficient and ATRX-proficient angiosarcomas………… 68 表目錄 Table 1 ATRX loss, ALT and their correlations in cytogenetically complex sarcomas………………………………………………………. 69 Table 2 ATRX loss, ALT and their correlations in gene fusion-associated sarcomas, gastrointestinal stromal tumors and epithelioid sarcomas…… 70 Table 3 Clinicopathological features, immunohistochemistry, and FISH results of the leiomyosarcomas…………………………………………. 71 Table 4 Clinicopathological features of the leiomyosarcomas regarding ATRX loss and ALT status……………………………………………… 72 Table 5 ATRX loss, ALT and their correlations in uterine smooth muscle tumor with borderline/atypical histological features……………………. 73 Table 6 Univariate and multivariate analysis of overall survival in leiomyosarcomas………………………………………………………... 74 Table 7 DNA flow cytometry of leiomyosarcomas with clinicopathological features………………………………………………………………….. 75 Table 8 Clinical information of the angiosarcomas…………………….. 76 Table 9 Clinicopathological features of the angiosarcomas regarding ATRX loss and ALT status……………………………………………… 77 | |
dc.language.iso | en | |
dc.title | 替代性端粒延長機制以及ATRX/DAXX蛋白質之失去表現於肉瘤之關係及臨床病理特性 | zh_TW |
dc.title | Alternative Lengthening of Telomeres and Loss of ATRX/DAXX Expression in Sarcomas with Clinicopathological Features | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 鄧述諄,鄭文芳,黃玄贏,紀秀華 | |
dc.subject.keyword | 肉瘤,ATRX,DAXX,替代性端粒延長機制,端粒, | zh_TW |
dc.subject.keyword | sarcoma,ATRX,DAXX,alternative lengthening of telomeres,telomere, | en |
dc.relation.page | 77 | |
dc.identifier.doi | 10.6342/NTU201801570 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 4.04 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。